(2-(thiophen-3-yl)phenyl)methanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-(thiophen-3-yl)phenyl)methanamine
• 英文别名: (2-thiophen-3-ylphenyl)methanamine
• 化学式: C₁₁H₁₁NS
• 分子量: 189.281
• InChiKey: BBLNZSAKQHEICV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  54.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4H-吡咯并[2,3-d]噻唑-5-羧酸 、 (2-(thiophen-3-yl)phenyl)methanamine 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以34.6%的产率得到N-[(2-thiophen-3-ylphenyl)methyl]-4H-pyrrolo[2,3-d][1,3]thiazole-5-carboxamide
  参考文献：
  名称：

  EP3705481

  摘要：

  公开号：
• 作为产物：
  描述：

  3-噻吩硼酸 、 邻溴苄胺 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 1.5h， 以52%的产率得到(2-(thiophen-3-yl)phenyl)methanamine
  参考文献：
  名称：

  Synthesis and evaluation of imidazole-4,5- and pyrazine-2,3-dicarboxamides targeting dengue and yellow fever virus

  摘要：

  The results of a high-throughput screening assay using the dengue virus-2 replicon showed that the imidazole 4,5-dicarboxamide (I45DC) derivative (15a) has a high dengue virus inhibitory activity. Based on 15a as a lead compound, a novel class of both disubstituted I45DCs and the resembling pyrazine 2,3-dicarboxamides (P23DC5) were synthesized. Here, we report on their in vitro inhibitory activity against dengue virus (DENV) and yellow fever virus (YFV). Some of these first generation compounds have shown activity against both viruses in the micromolar range. Within this series, compound 15b was observed to display the highest antiviral potency against YFV with an EC50 = 1.85 mu M. In addition, compounds 20a and 20b both potently inhibited replication of DENV (EC50 = 0.93 mu M) in Vero cells. (c) 2014 The Authors. Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2014.09.062

文献信息

• On-Chip Screening of a Glycomimetic Library with C-Type Lectins Reveals Structural Features Responsible for Preferential Binding of Dectin-2 over DC-SIGN/R and Langerin
  作者：Laura Medve、Silvia Achilli、Sonia Serna、Fabio Zuccotto、Norbert Varga、Michel Thépaut、Monica Civera、Corinne Vivès、Franck Fieschi、Niels Reichardt、Anna Bernardi

  DOI：10.1002/chem.201802577

  日期：2018.9.25

  A library of mannose‐ and fucose‐based glycomimetics was synthesized and screened in a microarray format against a set of C‐type lectin receptors (CLRs) that included DC‐SIGN, DC‐SIGNR, langerin, and dectin‐2. Glycomimetic ligands able to interact with dectin‐2 were identified for the first time. Comparative analysis of binding profiles allowed their selectivity against other CLRs to be probed.

  合成了一个基于甘露糖和岩藻糖的糖模拟物库，并以微阵列格式针对一组包括DC-SIGN，DC-SIGNR，Langerin和dectin-2的C型凝集素受体（CLR）进行了筛选。首次鉴定出能够与dectin-2相互作用的拟模拟配体。结合概况的比较分析允许探测其对其他CLR的选择性。
• HETEROARYL AMIDE COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF
  申请人：Rui Jin Hospital Affiliated To Shanghai Jiao Tong University School of Medicine

  公开号：EP3705481A1

  公开（公告）日：2020-09-09

  The present invention relates to heteroaryl amide compounds, a preparation method therefor, pharmaceutical compositions thereof and applications thereof, and specifically, relates to a type of compounds having broad-spectrum tumor resistant activity, a preparation method therefor, pharmaceutical compositions containing the compounds, and uses of the compounds in the preparation of drugs for treating tumors.

  本发明涉及杂芳基酰胺化合物、其制备方法、药物组合物及其应用，特别是涉及一种具有广谱抗肿瘤活性的化合物、其制备方法、含有该化合物的药物组合物以及该化合物在制备治疗肿瘤药物中的用途。
• [EN] ANTI-TUMOR MULTIDRUG RESISTANCE OF HETEROARYL AMIDE COMPOUND, USE IN TREATMENT OF CANCERS AND PROTEIN-DRUG MOLECULAR COMPLEX<br/>[FR] COMPOSÉ DE TYPE AMIDE D'HÉTÉROARYLE UTILISABLE CONTRE LES TUMEURS MULTIRÉSISTANTES AUX MÉDICAMENTS ANTICANCÉREUX, UTILISATION DANS LE TRAITEMENT DE CANCERS, ET COMPLEXE MOLÉCULAIRE PROTÉINE-MÉDICAMENT<br/>[ZH] 杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途和蛋白质-药物分子复合物
  申请人：RUI JIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

  公开号：WO2019196111A1

  公开（公告）日：2019-10-17

  一种作为微管抑制剂的杂芳基酰胺类化合物的抗肿瘤多药耐药性、治疗癌症的用途以及蛋白质-药物分子复合物。从使用通过致癌RAS转化的细胞的高通量药物筛选，鉴定了阻断细胞增殖的先导杂芳基酰胺化合物。构效关系分析表明，该系列的骨架(以I-28为示例)是肿瘤细胞生长的有效抑制剂。进一步分析表明，这种化合物在体外和体内都显示出抗肿瘤MDR的良好的药理学性质。总之，一种由I-28代表的新型骨架，该骨架可以开发为癌症治疗剂，特别是对于肿瘤多重抗性。
• Saudi, Milind; Zmurko, Joanna; Kaptein, Suzanne, European Journal of Medicinal Chemistry, 2016, vol. 121, p. 158 - 168
  作者：Saudi, Milind、Zmurko, Joanna、Kaptein, Suzanne、Rozenski, Jef、Gadakh, Bharat、Chaltin, Patrick、Marchand, Arnaud、Neyts, Johan、Van Aerschot, Arthur

  DOI：——

  日期：——
• Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
  申请人：Cook Caroline Mary

  公开号：US20080275078A1

  公开（公告）日：2008-11-06

  The invention provides a compound of formula (I) or a salt thereof: wherein: R 1 is C 1-3 alkyl, C 1-3 fluoroalkyl, or —CH 2 CH 2 OH; R 2 is hydrogen, methyl or C 1 fluoroalkyl; R 3 is of sub-formula (aa) or (bb): wherein Y is NCONH 2 and n 1 is 0 or 1; R 4 is H; and R 5 is a group of the sub-formula (x), (y), (y1) or (z): These compounds are PDE4 inhibitors.